Sujal Shah's Insider Trades & SAST Disclosures
Sujal Shah's most recent trade in Cymabay Therapeutics Inc was a trade of 800,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 22, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Sujal Shah.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 800,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 649,999 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 621,101 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 536,032 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 357,500 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 314,120 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 310,420 | 0 (0%) | 0% | - | Common Stock | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 284,712 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 146,875 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 96,250 | 0 (0%) | 0% | - | Common Stock | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 90,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 88,351 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 50,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 47,916 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Mar 2024 | 39,375 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 52,084 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.72 per share. | 13 Mar 2024 | 52,084 | 345,909 (0%) | 0% | 1.7 | 89,584 | Common Stock |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 22,076 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.05 per share. | 13 Mar 2024 | 22,076 | 404,381 (0%) | 0% | 4.1 | 89,408 | Common Stock |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 18,899 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.21 per share. | 13 Mar 2024 | 18,899 | 364,808 (0%) | 0% | 9.2 | 174,060 | Common Stock |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 14,625 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.06 per share. | 13 Mar 2024 | 14,625 | 293,825 (0%) | 0% | 1.1 | 15,503 | Common Stock |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 14,372 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.43 per share. | 13 Mar 2024 | 14,372 | 382,305 (0%) | 0% | 8.4 | 121,156 | Common Stock |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 11,649 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.00 per share. | 13 Mar 2024 | 11,649 | 279,200 (0%) | 0% | 10 | 116,490 | Common Stock |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 3,125 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.69 per share. | 13 Mar 2024 | 3,125 | 367,933 (0%) | 0% | 11.7 | 36,531 | Common Stock |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 2,288 | 12,845 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.78 per share. | 13 Mar 2024 | 2,288 | 406,669 (0%) | 0% | 5.8 | 13,225 | Common Stock |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.00 per share. | 13 Mar 2024 | 1 | 406,670 (0%) | 0% | 3 | 3 | Common Stock |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 1 | 35,799 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Shah Sujal | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 357,500 | 357,500 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Shah Sujal | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 96,250 | 267,551 (0%) | 0% | 0 | Common Stock | |
| Cymabay Therapeutics Inc | Shah Sujal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.99 per share. | 11 Dec 2023 | 63,975 | 171,301 (0%) | 0% | 20.0 | 1,278,649 | Common Stock |
| Cymabay Therapeutics Inc | Shah Sujal | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 11 Dec 2023 | 63,975 | 235,276 (0%) | 0% | 5 | 319,875 | Common Stock |
| Cymabay Therapeutics Inc | Shah Sujal | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 31,036 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 20,856 | 0 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 12,973 | 0 | - | - | Stock Appreciation Right | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 11 Dec 2023 | 890 | 172,191 (0%) | 0% | 5 | 4,450 | Common Stock |
| Cymabay Therapeutics Inc | Shah Sujal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.81 per share. | 11 Dec 2023 | 890 | 171,301 (0%) | 0% | 20.8 | 18,521 | Common Stock |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 800,000 | 800,000 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 1.95 per share. | 06 Jun 2022 | 51,301 | 171,301 (0%) | 0% | 2.0 | 100,037 | Common Stock |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 650,000 | 650,000 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 287,000 | 287,000 | - | - | Employee Stock Option (right to buy) | |
| Cymabay Therapeutics Inc | Sujal Shah | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2020 | 558,108 | 558,108 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges